Beam Therapeutics is trading at $24.13, with a -4.15% move, as investors continue weighing updated BEAM-302 Phase 1/2 safety findings.
- Infusion-related reactions affected 41% of patients.
- One patient experienced transient Grade 3 liver-enzyme elevations, despite durable efficacy.
- Shares also faced broader pressure as major U.S. indices declined amid hotter inflation signals and heightened interest-rate concerns.